|
CN102481271A
(zh)
|
2009-05-11 |
2012-05-30 |
博格生物系统有限责任公司 |
利用表观代谢转变剂、多维细胞内分子或环境影响剂治疗代谢障碍的方法
|
|
PT2435825E
(pt)
|
2009-05-27 |
2015-11-02 |
Biotempus Ltd |
Métodos para o tratamento de doenças
|
|
ES2928585T3
(es)
*
|
2010-09-21 |
2022-11-21 |
Proteomics Int Pty Ltd |
Biomarcadores asociados con prediabetes, diabetes y condiciones relacionadas con diabetes
|
|
PT2691112T
(pt)
*
|
2011-03-31 |
2018-07-10 |
Merck Sharp & Dohme |
Formulações estáveis de anticorpos para o recetor pd-1 humano de morte programada e tratamentos relacionados
|
|
CA2832324C
(en)
|
2011-04-04 |
2022-03-15 |
Berg Llc |
Methods of treating central nervous system tumors
|
|
ES2616289T3
(es)
*
|
2012-03-01 |
2017-06-12 |
Miltenyi Biotec Gmbh |
Separación de neuronas vivas intactas
|
|
WO2013169693A1
(en)
*
|
2012-05-09 |
2013-11-14 |
Bristol-Myers Squibb Company |
Methods of treating cancer using an il-21 polypeptide and an anti-pd-1 antibody
|
|
US20150177250A1
(en)
*
|
2012-06-18 |
2015-06-25 |
Mayo Foundation For Medical Education And Research |
Determination of efficient time(s) for chemotherapy delivery
|
|
UA117466C2
(uk)
|
2012-12-13 |
2018-08-10 |
Мерк Шарп Енд Доме Корп. |
СТАБІЛЬНИЙ СКЛАД У ВИГЛЯДІ РОЗЧИНУ АНТИТІЛА ДО IL-23p19
|
|
NZ713868A
(en)
|
2013-04-08 |
2021-12-24 |
Berg Llc |
Treatment of cancer using coenzyme q10 combination therapies
|
|
SMT202100065T1
(it)
|
2013-05-02 |
2021-03-15 |
Anaptysbio Inc |
Anticorpi diretti contro la proteina della morte programmata (pd-1)
|
|
KR102370843B1
(ko)
|
2013-09-04 |
2022-03-04 |
버그 엘엘씨 |
코엔자임 q10의 연속주입에 의한 암치료 방법
|
|
WO2015048312A1
(en)
|
2013-09-26 |
2015-04-02 |
Costim Pharmaceuticals Inc. |
Methods for treating hematologic cancers
|
|
SG10201804945WA
(en)
|
2013-12-12 |
2018-07-30 |
Shanghai hengrui pharmaceutical co ltd |
Pd-1 antibody, antigen-binding fragment thereof, and medical application thereof
|
|
PE20170255A1
(es)
|
2014-01-24 |
2017-03-22 |
Dana Farber Cancer Inst Inc |
Moleculas de anticuerpo que se unen a pd-1 y usos de las mismas
|
|
HUE045065T2
(hu)
|
2014-01-31 |
2019-12-30 |
Novartis Ag |
TIM-3 antitest molekulák és felhasználásaik
|
|
KR20240144452A
(ko)
*
|
2014-03-05 |
2024-10-02 |
브리스톨-마이어스 스큅 컴퍼니 |
항-pd-1 항체 및 또 다른 항암제의 조합물을 이용한 신장암의 치료
|
|
KR102442436B1
(ko)
|
2014-03-14 |
2022-09-15 |
노파르티스 아게 |
Lag-3에 대한 항체 분자 및 그의 용도
|
|
TWI693232B
(zh)
|
2014-06-26 |
2020-05-11 |
美商宏觀基因股份有限公司 |
與pd-1和lag-3具有免疫反應性的共價結合的雙抗體和其使用方法
|
|
KR20170060042A
(ko)
|
2014-09-13 |
2017-05-31 |
노파르티스 아게 |
Alk 억제제의 조합 요법
|
|
JP6991857B2
(ja)
|
2014-10-10 |
2022-01-13 |
イデラ ファーマシューティカルズ インコーポレイテッド |
Ｔｌｒ９アゴニストをチェックポイント阻害剤と共に用いるがんの治療
|
|
JP6821560B2
(ja)
|
2014-10-21 |
2021-01-27 |
サイクロン ファーマシューティカルズ インターナショナル エルティーディー．Ｓｃｉｃｌｏｎｅ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｔｅｒｎａｔｉｏｎａｌ Ｌｔｄ． |
免疫刺激剤による癌治療
|
|
EP3212670B1
(en)
*
|
2014-10-29 |
2020-12-23 |
Five Prime Therapeutics, Inc. |
Combination therapy for cancer
|
|
JP2016148623A
(ja)
*
|
2015-02-13 |
2016-08-18 |
京都府公立大学法人 |
大腸がんの検出方法
|
|
AU2016249981B2
(en)
|
2015-04-13 |
2022-02-17 |
Five Prime Therapeutics, Inc. |
Combination therapy for cancer
|
|
TWI773646B
(zh)
|
2015-06-08 |
2022-08-11 |
美商宏觀基因股份有限公司 |
結合lag-3的分子和其使用方法
|
|
HRP20211058T8
(hr)
|
2015-07-29 |
2021-11-26 |
Novartis Ag |
Kombinirane terapije koje sadrže molekule antitijela protiv lag-3
|
|
HUE068868T2
(hu)
|
2015-07-30 |
2025-02-28 |
Macrogenics Inc |
PD-1-hez kötõdõ molekulák és alkalmazásukra szolgáló eljárások
|
|
JP6666916B2
(ja)
*
|
2015-08-06 |
2020-03-18 |
積水メディカル株式会社 |
腎疾患の検査方法
|
|
EP4458417A3
(en)
|
2015-08-11 |
2025-02-19 |
Wuxi Biologics Ireland Limited |
Novel anti-pd-1 antibodies
|
|
WO2017087576A1
(en)
|
2015-11-16 |
2017-05-26 |
Berg Llc |
Methods of treatment of temozolomide-resistant glioma using coenzyme q10
|
|
IL260021B
(en)
|
2015-12-14 |
2022-09-01 |
Macrogenics Inc |
Bispecific molecules that are immunoreactive for pd1 and ctla4 and methods for using them
|
|
JP7137474B2
(ja)
|
2016-03-15 |
2022-09-14 |
メルサナ セラピューティクス，インコーポレイティド |
ＮａＰｉ２ｂ標的化抗体－薬物コンジュゲート及びその使用方法
|
|
US20180021270A1
(en)
*
|
2016-07-21 |
2018-01-25 |
Berg Llc |
Methods for the treatment of cancer using coenzyme q10 in combination with immune checkpoint modulators
|
|
WO2018022438A1
(en)
*
|
2016-07-29 |
2018-02-01 |
Eli Lilly And Company |
Combination therapy with merestinib and anti-pd-l1 or anti-pd-1 inhibitors for use in the treatment of cancer
|
|
JP2019533458A
(ja)
|
2016-11-01 |
2019-11-21 |
アナプティスバイオ インコーポレイティッド |
プログラム死１（ｐｄ−１）に対する抗体
|
|
US11135307B2
(en)
|
2016-11-23 |
2021-10-05 |
Mersana Therapeutics, Inc. |
Peptide-containing linkers for antibody-drug conjugates
|
|
AU2018206481B2
(en)
|
2017-01-09 |
2025-02-27 |
Tesaro, Inc. |
Methods of treating cancer with anti-PD-1 antibodies
|
|
US20180271996A1
(en)
|
2017-02-28 |
2018-09-27 |
Mersana Therapeutics, Inc. |
Combination therapies of her2-targeted antibody-drug conjugates
|
|
JP7257967B2
(ja)
*
|
2017-05-01 |
2023-04-14 |
ザ チルドレンズ メディカル センター コーポレーション |
抗ｐｄ１抗体試薬に関する方法および組成物
|
|
JOP20190260A1
(ar)
|
2017-05-02 |
2019-10-31 |
Merck Sharp & Dohme |
صيغ ثابتة لأجسام مضادة لمستقبل الموت المبرمج 1 (pd-1) وطرق استخدامها
|
|
JP7382232B2
(ja)
|
2017-05-02 |
2023-11-16 |
メルク・シャープ・アンド・ドーム・エルエルシー |
抗ｌａｇ３抗体の製剤および抗ｌａｇ３抗体と抗ｐｄ－１抗体との共製剤
|
|
WO2018225063A1
(en)
*
|
2017-06-04 |
2018-12-13 |
Rappaport Family Institute For Research In The Medical Sciences |
Method of predicting personalized response to cancer treatment with immune checkpoint inhibitors and kits therefor
|
|
US12016900B2
(en)
|
2017-06-04 |
2024-06-25 |
Rappaport Family Institute For Research In The Medical Sciences |
Method of treating cancer with an immune checkpoint inhibitor in combination with another therapeutic agent
|
|
US12070489B2
(en)
|
2018-12-12 |
2024-08-27 |
Rappaport Family Institute For Research In The Medical Sciences |
Method of treating cancer with a cancer therapy in combination with another therapeutic agent
|
|
EP3681535A1
(en)
|
2017-09-13 |
2020-07-22 |
Five Prime Therapeutics, Inc. |
Combination anti-csf1r and anti-pd-1 antibody combination therapy for pancreatic cancer
|
|
US11946937B2
(en)
*
|
2017-09-13 |
2024-04-02 |
Mayo Foundation For Medical Education And Research |
Identification and monitoring of apoptosis inhibitor of macrophage
|
|
WO2019104289A1
(en)
|
2017-11-27 |
2019-05-31 |
Mersana Therapeutics, Inc. |
Pyrrolobenzodiazepine antibody conjugates
|
|
CN111757757A
(zh)
|
2017-12-21 |
2020-10-09 |
梅尔莎纳医疗公司 |
吡咯并苯并二氮呯抗体共轭物
|
|
US12448448B2
(en)
|
2018-06-20 |
2025-10-21 |
Incyte Corporation |
Anti-PD-1 antibodies and uses thereof
|
|
WO2020081408A1
(en)
|
2018-10-18 |
2020-04-23 |
Merck Sharp & Dohme Corp. |
Formulations of anti-rsv antibodies and methods of use thereof
|
|
CN113365664A
(zh)
|
2018-10-29 |
2021-09-07 |
梅尔莎纳医疗公司 |
具有含肽接头的半胱氨酸工程化的抗体-药物缀合物
|
|
MX2021004928A
(es)
|
2018-10-31 |
2021-06-08 |
Merck Sharp & Dohme Llc |
Cristales de anticuerpo anti-pd-1 humano y metodos de uso de los mismos.
|
|
EP3876990A4
(en)
|
2018-11-07 |
2023-09-06 |
Merck Sharp & Dohme LLC |
CO-FORMULATIONS OF ANTI-LAG3 ANTIBODIES AND ANTI-PD-1 ANTIBODIES
|
|
EP3924521A4
(en)
|
2019-02-15 |
2023-03-29 |
IncellDx, Inc. |
BLADDER-ASSOCIATED SAMPLES TESTING, IDENTIFICATION AND TREATMENT OF BLADDER-ASSOCIATED NEOPLASIA, AND KITS FOR USE THEREON
|
|
WO2020227431A1
(en)
|
2019-05-06 |
2020-11-12 |
Brown University |
Bispecific antibodies against chi3l1 and pd1 with enhanced t cell-mediated cytotoxic effects on tumor cells
|
|
WO2021061749A1
(en)
|
2019-09-24 |
2021-04-01 |
Mirati Therapeutics, Inc. |
Combination therapies
|
|
WO2023017525A1
(en)
|
2021-08-11 |
2023-02-16 |
OncoHost Ltd. |
Predicting patient response
|
|
WO2023236099A1
(en)
*
|
2022-06-08 |
2023-12-14 |
Zhejiang Shimai Pharmaceutical Co., Ltd. |
Antibodies against enpp3 and uses thereof
|
|
EP4650781A1
(en)
*
|
2023-01-10 |
2025-11-19 |
Toru Miyazaki |
Method for diagnosing cancer
|
|
WO2025034883A1
(en)
|
2023-08-08 |
2025-02-13 |
Quanta Therapeutics, Inc. |
Combination therapies with kras modulators
|
|
WO2025106905A1
(en)
|
2023-11-17 |
2025-05-22 |
Quanta Therapeutics, Inc. |
Combination therapies with a kras modulator and an immunomodulator inhibitor
|
|
WO2026060384A1
(en)
|
2024-09-16 |
2026-03-19 |
Quanta Therapeutics, Inc. |
Combination therapies with kras modulators
|